Loading interface...

Tabi 50 mg Tablet

Manufactured byDr. Reddys Laboratories Ltd.
ContainsBicalutamide
Description
Tabi 50 mg Tablet is a non-steroidal anti-cancer medicine used in men along with other specific agents for the treatment of prostate cancer. This medicine is not recommended for use in females, children, and adolescents.

Side effects

Major & minor side effects for Tabi 50 mg Tablet

  • Hypersensitivity
  • Abdominal pain
  • Nausea and vomiting
  • Flu like symptoms
  • Unusual bleeding or bruising
  • Loss of appetite
  • Yellowing of skin and eyes
  • Difficulty with passing uine
  • Gynacomastia
  • Difficulty in breathing

Uses of Tabi 50 mg Tablet

What is it prescribed for?

  • Prostate cancer
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to show its action is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in women.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in women.

Allergy

This medicine is not recommended for use in patients with a known allergy to bicalutamide or any other components present along with it.

Pregnancy

This medicine is not recommended for use in pregnant women.
Warnings for special population

Pregnancy

This medicine is not recommended for use in women.

Breast-feeding

This medicine is not recommended for use in women.
General warnings

Use in females

This medicine is not recommended for use in female patients.

Contraception

Effective contraception methods must be used during treatment with this medicine and until 130 days after stopping the therapy.

Use in pediatrics

This medicine is not recommended for use in children and adolescents.

Diabetes Mellitus

The combination of Tabi 50 mg Tablet and GnRH agonists should be used with caution in patients with a history of diabetes mellitus due to the increased risk of elevated blood glucose levels. Close monitoring of blood glucose levels is recommended for these patients.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Pimozide

Leflunomide

Lomitapide

Disease interactions

Disease

Information not available.
Food interactions
Information not available.
Lab interactions
Information not available.
Take Tabi 50 mg Tablet as instructed by the doctor. Do not take in larger amounts than advised/prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
Tabi 50 mg Tablet acts by blocking the action of male hormones on the prostate gland, thereby stopping the growth and spread of cancer cells.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Androgen antagonists, Hormonal antineoplastic agents

Schedule

Schedule H

Bicalutamide: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 18 August 2017]. Available from:

https://medlineplus.gov/druginfo/meds/a697047.html

DailyMed - BICALUTAMIDE- bicalutamide tablet [Internet]. Dailymed.nlm.nih.gov. 2017 [cited 18 August 2017]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c295b64-ec39-42ec-9f02-da5b42e775e1&audience=consumer

[Internet]. 2017 [cited 18 August 2017]. Available from:

https://www.medicines.org.uk/emc/PIL.25779.latest.pdf

Bicalutamide - DrugBank [Internet]. Drugbank.ca. 2017 [cited 18 August 2017]. Available from:

https://www.drugbank.ca/drugs/DB01128

Bicalutamide [Internet]. Snomedbrowser.com. 2017 [cited 18 August 2017]. Available from:

http://www.snomedbrowser.com/Codes/Details/386908000
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 29 Aug 2017

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.